Skip to main content

Table 2 Reason for discontinuation and the timing

From: Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance

Reason for discontinuationa Timing of discontinuation, n (%)
Total Day 1- < 29 Day 29- < 61 Day 61- < 91 Day 91- < 121 Day 121- < 181 Day 181- < 270 Day 270- < 365 Day ≥365
1. Adverse events 43 (21.4) 12 (6.0) 9 (4.5) 4 (2.0) 4 (2.0) 5 (2.5) 7 (3.5) 2 (1.0) 0 (0.0)
2. Worsening of symptoms 14 (7.0) 2 (1.0) 2 (1.0) 1 (0.5) 1 (0.5) 2 (1.0) 3 (1.5) 3 (1.5) 0 (0.0)
3. Improved symptoms 32 (15.9) 4 (2.0) 1 (0.5) 5 (2.5) 4 (2.0) 3 (1.5) 8 (4.0) 6 (3.0) 1 (0.5)
4. Request for discontinuation from patient or family 68 (33.8) 14 (7.0) 13 (6.5) 5 (2.5) 5 (2.5) 7 (3.5) 13 (6.5) 9 (4.5) 2 (1.0)
5.Transfer to another hospital 21 (10.4) 2 (1.0) 4 (2.0) 0 (0.0) 0 (0.0) 7 (3.5) 4 (2.0) 4 (2.0) 0 (0.0)
6. Lost to follow-up 38 (18.9) 7 (3.5) 7 (3.5) 3 (1.5) 4 (2.0) 5 (2.5) 7 (3.5) 5 (2.5) 0 (0.0)
7. Other 15 (7.5) 2 (1.0) 1 (0.5) 0 (0.0) 2 (1.0) 7 (3.5) 2 (1.0) 0 (0.0) 1 (0.5)
Totalb 201 (100.0) 37 (18.4) 34 (16.9) 16 (8.0) 17 (8.5) 30 (14.9) 39 (19.4) 24 (11.9) 4 (2.0)
  1. a: Multiple responses were allowed in a patient. Concurrent reasons are: 3 and 4 (n = 9), 1 and 4 (n = 8), 1 and 2 (n = 4), 1 and 7 (n = 3), 4 and 7 (n = 2), 2 and 4 (n = 1), 1 and 6 (n = 1), 1, 2, and 4 (n = 1)
  2. b: If more than one reason for discontinuation was observed in a patient, the data were summarized as 1 patient